<DOC>
	<DOC>NCT02319005</DOC>
	<brief_summary>The purpose of this study was to evaluate the safety and efficacy of revusiran (ALN-TTRSC) in patients with transthyretin (TTR) mediated Familial Amyloidotic Cardiomyopathy. Dosing has been discontinued; patients are being followed-up for safety.</brief_summary>
	<brief_title>ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)</brief_title>
	<detailed_description />
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Amyloid Neuropathies</mesh_term>
	<mesh_term>Amyloidosis, Familial</mesh_term>
	<mesh_term>Amyloid Neuropathies, Familial</mesh_term>
	<criteria>Documented TTR mutation Amyloid deposits in cardiac or noncardiac tissue Medical history of heart failure Evidence of cardiac involvement by echocardiogram Has known primary amyloidosis (AL), leptomeningeal amyloidosis, nonFAC hereditary cardiomyopathy, hypertensive cardiomyopathy, or cardiomyopathy due to valvular heart disease Has known peripheral vascular disease affecting ambulation Has a Polyneuropathy Disability score &gt;2 Has a New York Heart Association (NYHA) classification of IV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Cardiomyopathy</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>FAC</keyword>
	<keyword>Amyloid</keyword>
	<keyword>Transthyretin</keyword>
	<keyword>TTR</keyword>
	<keyword>RNAi therapeutic</keyword>
</DOC>